CA1174600A - Encapsulation of live animal cells - Google Patents
Encapsulation of live animal cellsInfo
- Publication number
- CA1174600A CA1174600A CA000392774A CA392774A CA1174600A CA 1174600 A CA1174600 A CA 1174600A CA 000392774 A CA000392774 A CA 000392774A CA 392774 A CA392774 A CA 392774A CA 1174600 A CA1174600 A CA 1174600A
- Authority
- CA
- Canada
- Prior art keywords
- cells
- polymer
- encapsulated
- viable
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Abstract
ABSTRACT OF THE DISCLOSURE
Viable mammalian cells are encapsulated in a polymeric membrane to form microencapsulated beads ready for introduction into a host body. The polymeric membrane allows passage therethrough of cell substrates and secretions, but prevents passage of larger molecules such as proteinaceous antibodies.
In this way viable cells secreting essential products such as pancreatic islet cells secreting insulin can be transplanted into a host, and be protected against the immune reactions of the antibodies of the host which would otherwise reject the foreign cells. The cells are encapsulated from suspension in a non-solvent such as PPG, by addition thereto of a solution of a polymer (e.g. an acrylic/methacrylic acid esters copolymer) in dimethylsulfoxide. The polymer precipitates onto the cells to encapsulate them, and the supernatants are removed.
Viable mammalian cells are encapsulated in a polymeric membrane to form microencapsulated beads ready for introduction into a host body. The polymeric membrane allows passage therethrough of cell substrates and secretions, but prevents passage of larger molecules such as proteinaceous antibodies.
In this way viable cells secreting essential products such as pancreatic islet cells secreting insulin can be transplanted into a host, and be protected against the immune reactions of the antibodies of the host which would otherwise reject the foreign cells. The cells are encapsulated from suspension in a non-solvent such as PPG, by addition thereto of a solution of a polymer (e.g. an acrylic/methacrylic acid esters copolymer) in dimethylsulfoxide. The polymer precipitates onto the cells to encapsulate them, and the supernatants are removed.
Description
This invention relates to encapsulated biological cells and method of preparing microencapsulated cells in a form suitable for use in medical treatment.
Many disorders in mammals and other living bodies are due to the lack of proper functioning natural cells of one type or another, with consequent lack of essential substances normally secreted by such cells. For example, diabetes is a disorder resulting from lack of properly functioning pancreatic islet cells, which normally produce and secrete insulin in response to glucose. Attempts to alleviate such conditions by transplantations of living, functioning animal cells, e.g.
pancreatic islets, are limited by the immune rejection of these cells by the host body. Although the immune system can be artificially suppressed through chemotherapy and the transplant given an opportunity to succeed, this approach is not practical for large scale transplantations. The benefit to diabetics of such a pancreatic islet transplant would be enormous since not only would their reliance on exogenous insulin be reduced, but the insulin would be delivered in the natural control mode avoiding the periodic variation in glucose level associated with conventional therapy. It is believed that these variations are responsible for the degenerative complications of diabetes.
As an alternative to chemotherapy, it has been possible to separate the "foreign" cells from the host by a membrane which selectively permits substrate, product and other 46~0 biochemical agent exchange between the foreign cells and the host tissues but which prevents the higher molecular weight antibodies of the host from contacting the foreign cells. This has been achieved for pancreatic islets by separating rat islets fro~ the host's blood (e.g. monkey) by a hollow fibre ultrafiltration membrane with a molecular weight "cut off" of 50,000 (see Sun et al, "Diabetes", 26, 1136 (1977) ). This membrane which is preformed freely permits glucose and insulin transport but prevents the circulating antibodies (M.W. 150,000 typically) from crossing into the cell compartment.
Unfortunately, a blood-material interface is introduced in this kind of device with the normal consequences of this interface (coagulation, thrombosis). The development of a differen~ form of suitably protected living animal cells for transplantation into a host body is therefore desirable.
It is known to prepare small encapsulated beads containing soluble enzymes or whole microbial cells (see for example Chang et al, Cdn. J. Phys. Pharm., 44, 115 (1966);
Klein et al, Proceed. I European Congress of Biotechnology (1978); Jack and Zajic, Adv. Biochem. Eng., 5, 125 (1977)).
However, techniques described therein are not applicable to living animal cells, which are much more fragile.
The present invention provides small beads comprising a few viable cells, the cells being completely covered with 117466~
polymer membrane formed in situ. The beads can be injected or otherwise introduced into the appropriate body compartment (such as the peritoneal cavity, in the case of pancreatic islet cells). The thrombosis problems referred to above are avoided, since the injected beads are put into direct contact withe live tissue, not with blood. The beads have a very large surface area. The membrane is a water insoluble polymeric material.The membrane and the reagents used in the encapsulation process are chosen to produce encapsulated but still viable cells, the membrane permitting passage therethrough of cell substrates, cell secretagogues, cell secretions and metabolic regulator, but inhibiting or preventing the passage of antibodies therethrough which might cause an immune reaction and rejection of the cells by the host body.
Thus according to the first aspect of the present invention, there is provided a process for preparing micro~encapsulated viable mammalian cells for introduction into host, living mammalian tissue, which comprises:
preparing an aqueous suspension of said viable mammalian cells;
bringing said aqueous suspension into contact with a solution of a biocompatible, water-insoluble polymer in a polar, non-toxic liquid optionally in the presence also of a water immiscible suspending medium, and forming a suspension having aqueous droplets containing said viable cells dispersed in a 11746(~0 hydrophobic liquid medium;
causing the polymer to precipitate at the interface of the aqueous, cell-containing droplets and the hydrophobic phase so as to encapsulate some at least of the cells in said droplets with a membrane of said polymer, separating the bulk of the hydrophobic medium and solvents from the encapsulated cellular material.
According to a second aspect of the invention, there is provided micro-encapsulated viable mammalian cells, said cells being in the form of discrete beads each containing a small number of said viable cells, and each bead being encapsulated in a semi-permeable, water-insoluble, biocompatible polymeric membrane capable of allowing passage therethrough of cell -substrate material and cell secretions, but effectively preventing passage therethrough of high molecular weight antibodies of a living organism.
In one preferred method of preparation of micro encapsulated cells according to the present invention, the cell aqueous suspension is dispersed, with agitation, in a suspending medium to form an emulsion with a continuous hydrophobic phase and a discontinuous aqueous phase comprising droplets each containing a small amount of viable cells. Then the polymer solution is added to the emulsion. Precipitation of the polymer can then be caused either by addition to the mixture of an additional non-solvent for the polymer, or substantially .; .
.. . .
1~7~6~0 spontaneously due to the non-solvent character of the suspending medium. In such a procedure, the suspending medium should be a relatively high molecular weight, hydrophobic, non-toxic, non-cell-penetrating liquid. It should be miscible with the polymer solution, yet be preferably a non-solvent for the polymer. Preferred are mineral oils (hydrocarbon liquids with six or more carbon atoms per molecule), corn oils, and polypropylene glycol (PPG). Most preferred is PPG, partly on account of its well established utility in the preservation of viable celIs for low temperature storage.
In an alternative procedure, the cell aqueous suspension may be added to the solution of the polymer in a suitable water immiscible solvent, to form a suspension thereof with discrete aqueous, cell-containing droplets therein. This suspension is then contacted with a suitable non-solvent for the polymer, to cause precipitation thereof at the water-solvent interface for micro encapsulation of the c~lls. The non-solvent for the polymer can be aqueous or hydrophobic, depending upon the solvent chosen for the polymer. Since the polymer solvent will normally be one of medium polarity, either type of non-solvent will normally be satisfactory.
A wide variety of polymers are available for use in the present invention. The polymer should be capable of ready solidification to form a membrane having the desired transport properties, and insoluble in water or saline at cellular pH.
117~t30 The desired transport properties, e.g. permeability in vivo, require that the polymer have a degree of polarity. The polymer membrane should contain 20-90~ water at equilibrium. The polymer should be non-toxic in solution, and biocombatible in solid form, i.e. free from elutable contaminants, sterilizable, implantable without causing inflammatory or immune response, and either non-biodegradable or of controlled biodegradability.
Examples of suitable polymers include polyacrylates and copolymers with acrylic acid, methacrylic acid and esters thereof, cellulose based polymers, copolymers containing acrylamides, N-vinyl pyrrolidone, styrene sulphonate, vinyl pyridine, vinyl alcohol, allyl alcohol and the like. A
mostpreferred polymer is a copolymer of acrylic acid ester and methacrylic acid ester, with small amounts of quaternary ammonium groups. A specific example of such a preferred polymer, commercially available, is that known under the trade mark EUDRAGIT, manufactured by Rohm Pharma GMBH, of Darmstadt, W.Germany. This product is commonly used to coat dry tablets in slow release formulations.
The precise manner in which the polymer is precipitated onto the cells to form the membrane is not critical so long as a satisfactory encapsulation of a few cells to form encapsulated beads is achieved, without of course affecting the cells themselves. In a preferred method, the polymer solution in DMSO
is added to the well stirred aqueous cell emulsion in PPG, with :117~6~0 the result that the polymer precipitates at the interface of the water droplets to form a membrane shell about each droplet. In one alternative where, the cell emulsion is dispersed in the polymer solution, the polymer solution (containing dispersed cells) is added slowly to a polymer non-solvent to precipitate the polymer around the aqueous droplets. In another alternative, the polymer solution (containing dispersed cells) is added slowly to a polymer non-solvent immiscible with the polymer solvent, and then a second, miscible non-solvent is added slowly to this mixture to precipitate the polymer. Both the non-solvent and the solvent should of course be non-toxic, have low water solubility and high molecular weight. The non-solvent may be an isotonic aqueous solution at cellular pH, A with or without surfactants (e.g. Tweens, Pluronics etc.) or other additives such as albumin. The non-solvent may be an organic liquid miscible with the polymer solvent, non-toxic, and hydrophobic ana of high molecular weight (greater than 150) so that it does not penetrate the cells. Suitable examples are mineral oils, polyethers and polyether copolymers, natural and synthetic di-and tri-glycerides (e.g. corn oil, cotton seed oil etc.) and the like.
The choice of polymer solvent must be made with care.
Since, in order to provide a membrane with suitable transport properties when encapsulating the cells, a polar polymer must be used, the solvent liquid must also have a degree of polarity.
~ r~ `k~
At the same time, one must choose a polymer having low specific toxicity, often an incompatible requirement. The best solvents for use in the present invention are either relatively high molecular weight, medium polarity, non-toxic solvents with no or negligible water solubility, such as dimethyl phthalate, dibutyl phthalate, and the like, or highly polar water soluble solvents such as dimethyl-sulfoxide and the like. In the first alternative method of encapsulating the cells outlined above, in which the polymer solution is added to a suspension of aqueous cells in, e.g. polypropylene glycol, dimethyl sulfoxide (DMSO) is the most preferred solvent, since this process can utilise a water miscible solvent such as DMSO, which also has other advantageous characteristics. Suitable alternative solvents for this process are highly polar, water soluble, and tolerated by the cells at least to a limited extent. In the second and third processes where the aqueous cell suspension is dispersed in the polymer solution, then the polymer solvent must be water immiscible. In this case, the solvent should have intermediate polarity, very low toxicity, and be one which does not penetrate the cells. It should have a water solubility less than aboutO.5gm per 100 millilitres. Solvents containing moderately hydrogen bonding functional groups (ester, ether, carbonyl or S=O groups, for example) as set out in the "Polymer Handbook", srandrup and Immergut (Chapter 4), first edition, with a solubility parameter between 8 and 11, e.g. dialkyl phthalates ~17~ 3 and esters of dicarbo~ylic acids, are generally suitable. It is preferred to use solvents of molecular weight at least 150, otherwise the contact time of the solvent with the cells must be careully reduced. Most preferred solvents for use in this process are dibutyl phthalate, diethylphthalate and dimethylphthalate.
After the polymer has been precipitated to encapsulate the cells, it is necessary to separate the cells from the liquid residues. This can done by centrifuging after a suitable period of time, followed by decanting off the residual solvent/non-solvent mixture and washing to remove residues thereof. Great care should be taken to rinse DMSO from the cells. The cells should be washed repeatedly in aqueous solution of DMSO of progressively lower concentrations to minimize the osmotic gradient. Alternatively, the DMSO may be removed by dialysis during or after encapsulation. When dialysis is conducted during encapsulation, the bottom of the encapsulation chamber may be formed as a membrane permeable to DMSO but impermeable tothe hydrophobic non solvent, contacting a chamber containing saline. The encapsulation medium may be continuously dialysed against saline, in a separate unit, connected by a pump with the encapsulation unit.
It may be found advantageous to add various agents (e.g. albumin, clacium alginate and the like) to the initial cell emulsion to assist in preserving the cells during subsequent processing steps.
It may also be found advantageous to add a surfactant (e.g. PLURONIC L62*, from BASF Wyandotte) prior to centrifuging to assist in preventing the soft beads from coalescing during centrifugation. After separation, it is desirable to treat the encapsulated cell beads with an isotonic saline solution, with mixing, one or more times, to "harden" the membrane shell and prepare beads of appropriate quality and integrity. Then the viable cells are ready for preparation into appropriate dosage form, and administration to a body in an appropriate manner.
The invention is further illustrated in the following specific examples.
EXAMPLE l EUDRAGIT RL (Rohm Pharma Gmbh., Darmstadt, ~. Germany), -an acrylic acid ester/methacrylic acid ester copolymer containing a low content of quaternary ammonium groups was dissolved in a 75/25 (v/v) mixture of ethyl acetate and DMSO.
0.2 mL of this solution (27.4% w/v polymer was added, slowly, over a two minute period, to a well-stirred dispersion containing 0.4 mL of human whole blood or packed cells suspended in aqueous phosphate buffered saline (Red Cross Blood Bank, Toronto, Ontario) in 25 mL of mineral oil. Stirring was continued for a further 3 minutes.
5 mL of PBS (phosphate buffered saline) containing 15%
DMSO (v/v) was added to the dispersion and the mixture was centrifuged at low speed to remove the mineral oil supernatant.
*Trade Mark 46~)0 The DMSO was removed gradually in subsequent 5 mL washes followed by centrifugation with PBS containing progressively lower concentrations of DMSO (10%, 5%, 0~, DMSO).
Three further washes with pure PBS, followed by centrifugation at low speed, were used to separate free or partially encapsulated cells from the microcapsules.
Microscopic examination was used to assess qualitatively the effectiveness of the encapsulation process.
Cell lysis was quantified by spectrophotometric measurement of cyanmethemoglobin at 540 nm. Average capsule diameter was approximately 150 m. The cells, unchanged in colour, were encapsulated in clumps, but with the cell membrane distinctly separating individual cells. The cells were not uniformly distributed among the capsules, however.
With each wash the mixture was separated into three fractions:
micro-capsules containing cells, free cells and an aqueous supernatant containing some hemoglobin. The free cells which had been subject to the encapsulation conditions yet not encapsulated appeared intact microscopically (normal shape), took up oxygen freely, (turned bright pink when air was bubbled through an aliquot of resuspended cells) and lysed normally when placed in distilled water. In contrast, free cells after encapsulation using a pure DMSO solution of polymer were fixed, did not lyse in distilled water and had turned brown.
~1746~0 The estimated yield of encapsulated cells from whole blood was approximately 1-6% as determined by comparing the total amount of hemoglobin in the unencapsulated fractions (free cells and lysate) with the amount of hemoglobin in 12 drops of whole blood. Under the indicated experimental conditions, approximately 20% of the hemoglobin of the non-encapsulated cells was recovered as free hemoglobin during the aqueous washing steps. About 40-45% of this (i.e. 8-9% of the total) was recovered in the initial 15% DMSO/PBS wash; this represents the degree of cell lysis that occurred during both encapsulation and this initial wash step.
Encapsulated cells placed in distilled water lost hemoglobin slowly (overnight) to the surrounding fluid, indicating the low permeability of the EUDRAGIT capsules to proteins as large as hemoglobin. Spectrophotometric analysis of the distilled water supernatant indicated that the hemoglobin was not oxidized and that approximately 6% of the total cells were originally encapsulated, in agreement with the number estimated by hemoglobin balance for this batch of cells.
Hemoglobin did not leak from encapsulated cells placed in PBS, indicating that the encapsulated cells were intact, but were not fixed, lysing normally in hypotonic solutions. Removing the polymer coating by placing the capsules that had been in PBS in pure DMSO produced a brown pellet of fixed cells but no such pellet was found with the capsules that had been in distilled 11746Q(~
water, further indicating the intact state of the encapsulated cells.
Unlike conventional coacervation methods in which a non-solvent is added to a suspension of cells or other material in a polymer/solvent continuous medium to precipitate the polymer around the discrete phase, this method appears to rely on the high partition coefficient of DMSO between water and mineral oil. The DMSO solubilized the polymer in the mineral oil.
Because of the high partition coefficient, however, the DMSO was removed from the oil phase in the presence of the discrete aqueous phase. The removal of the solubilizing agent caused the polymer to precipitate at the water/oil interface. Accordingly the capsule was formed very rapidly ( 5 minutes), since the rate of capsule formation was limited by the rate of DMSO
removal and not by the slower rate of coacervate formation.
Other polar solvents (e.g. ethanol) were found to be appropriate for microcapsule formation but they were incompatible with the cells.
0.2 mL of washed packed red blood cells suspended in phosphate buffered saline was further dispersed in 5 mL of a 8 solution of EUDRAGIT RL in diethylphthalate. 4 mL of this mixture was dispersed in 20 mL of mineral oil to which 10 mL of corn oil was quickly added followed by stirring for 10 minutes.
After capsules had formed, a further 10 mL of corn oil was ~1746(~0 added, removed by decantation and followed by washing with 30 mL
of fresh corn oil and then 30 mL of mineral oil. The mineral oil phase was replaced with 10 mL PBS followed by centrifugation to yield hard, nonsticky, essentially spherical capsuls.
0.05 mL of washed packed red blood cells suspended in 0.05 mL of 9% bovine serum albumin aqueous solution was dispersed in 0.4 mLs of a 10% solution of Eudragit RL in dimethyl phthalate also containing 10% albumin. This mixture was added dropwise through an unstirred layer of corn oil (10 mL) into an unstirred bath of 2% albumin in PBS solution (100 mL). After all the cells were added the mixture was stirred for 15 minutes to further harden the capsules and remove the solvent. The capsules were recovered by centrifugation and washed twice with 2% albumin PBS to yield a hard granular product.
Encapsulated, viable mammalian cells according to the present invention have many useful applications of potential importance. For example, encapsulation of hepatocytes results in a functioning "artificial liver" for the treatment of acute hepatic coma or for drug detoxification. Encapsulation of interferon producing cells (e.g., human leukocytes, fibroblasts or lymphocytes) may facilitate the large scale production of interferon by increasing the surface-to-volume ratio of the culture, by increasing the stability of the cell and by simplifying the scale-up of the production process.
Many disorders in mammals and other living bodies are due to the lack of proper functioning natural cells of one type or another, with consequent lack of essential substances normally secreted by such cells. For example, diabetes is a disorder resulting from lack of properly functioning pancreatic islet cells, which normally produce and secrete insulin in response to glucose. Attempts to alleviate such conditions by transplantations of living, functioning animal cells, e.g.
pancreatic islets, are limited by the immune rejection of these cells by the host body. Although the immune system can be artificially suppressed through chemotherapy and the transplant given an opportunity to succeed, this approach is not practical for large scale transplantations. The benefit to diabetics of such a pancreatic islet transplant would be enormous since not only would their reliance on exogenous insulin be reduced, but the insulin would be delivered in the natural control mode avoiding the periodic variation in glucose level associated with conventional therapy. It is believed that these variations are responsible for the degenerative complications of diabetes.
As an alternative to chemotherapy, it has been possible to separate the "foreign" cells from the host by a membrane which selectively permits substrate, product and other 46~0 biochemical agent exchange between the foreign cells and the host tissues but which prevents the higher molecular weight antibodies of the host from contacting the foreign cells. This has been achieved for pancreatic islets by separating rat islets fro~ the host's blood (e.g. monkey) by a hollow fibre ultrafiltration membrane with a molecular weight "cut off" of 50,000 (see Sun et al, "Diabetes", 26, 1136 (1977) ). This membrane which is preformed freely permits glucose and insulin transport but prevents the circulating antibodies (M.W. 150,000 typically) from crossing into the cell compartment.
Unfortunately, a blood-material interface is introduced in this kind of device with the normal consequences of this interface (coagulation, thrombosis). The development of a differen~ form of suitably protected living animal cells for transplantation into a host body is therefore desirable.
It is known to prepare small encapsulated beads containing soluble enzymes or whole microbial cells (see for example Chang et al, Cdn. J. Phys. Pharm., 44, 115 (1966);
Klein et al, Proceed. I European Congress of Biotechnology (1978); Jack and Zajic, Adv. Biochem. Eng., 5, 125 (1977)).
However, techniques described therein are not applicable to living animal cells, which are much more fragile.
The present invention provides small beads comprising a few viable cells, the cells being completely covered with 117466~
polymer membrane formed in situ. The beads can be injected or otherwise introduced into the appropriate body compartment (such as the peritoneal cavity, in the case of pancreatic islet cells). The thrombosis problems referred to above are avoided, since the injected beads are put into direct contact withe live tissue, not with blood. The beads have a very large surface area. The membrane is a water insoluble polymeric material.The membrane and the reagents used in the encapsulation process are chosen to produce encapsulated but still viable cells, the membrane permitting passage therethrough of cell substrates, cell secretagogues, cell secretions and metabolic regulator, but inhibiting or preventing the passage of antibodies therethrough which might cause an immune reaction and rejection of the cells by the host body.
Thus according to the first aspect of the present invention, there is provided a process for preparing micro~encapsulated viable mammalian cells for introduction into host, living mammalian tissue, which comprises:
preparing an aqueous suspension of said viable mammalian cells;
bringing said aqueous suspension into contact with a solution of a biocompatible, water-insoluble polymer in a polar, non-toxic liquid optionally in the presence also of a water immiscible suspending medium, and forming a suspension having aqueous droplets containing said viable cells dispersed in a 11746(~0 hydrophobic liquid medium;
causing the polymer to precipitate at the interface of the aqueous, cell-containing droplets and the hydrophobic phase so as to encapsulate some at least of the cells in said droplets with a membrane of said polymer, separating the bulk of the hydrophobic medium and solvents from the encapsulated cellular material.
According to a second aspect of the invention, there is provided micro-encapsulated viable mammalian cells, said cells being in the form of discrete beads each containing a small number of said viable cells, and each bead being encapsulated in a semi-permeable, water-insoluble, biocompatible polymeric membrane capable of allowing passage therethrough of cell -substrate material and cell secretions, but effectively preventing passage therethrough of high molecular weight antibodies of a living organism.
In one preferred method of preparation of micro encapsulated cells according to the present invention, the cell aqueous suspension is dispersed, with agitation, in a suspending medium to form an emulsion with a continuous hydrophobic phase and a discontinuous aqueous phase comprising droplets each containing a small amount of viable cells. Then the polymer solution is added to the emulsion. Precipitation of the polymer can then be caused either by addition to the mixture of an additional non-solvent for the polymer, or substantially .; .
.. . .
1~7~6~0 spontaneously due to the non-solvent character of the suspending medium. In such a procedure, the suspending medium should be a relatively high molecular weight, hydrophobic, non-toxic, non-cell-penetrating liquid. It should be miscible with the polymer solution, yet be preferably a non-solvent for the polymer. Preferred are mineral oils (hydrocarbon liquids with six or more carbon atoms per molecule), corn oils, and polypropylene glycol (PPG). Most preferred is PPG, partly on account of its well established utility in the preservation of viable celIs for low temperature storage.
In an alternative procedure, the cell aqueous suspension may be added to the solution of the polymer in a suitable water immiscible solvent, to form a suspension thereof with discrete aqueous, cell-containing droplets therein. This suspension is then contacted with a suitable non-solvent for the polymer, to cause precipitation thereof at the water-solvent interface for micro encapsulation of the c~lls. The non-solvent for the polymer can be aqueous or hydrophobic, depending upon the solvent chosen for the polymer. Since the polymer solvent will normally be one of medium polarity, either type of non-solvent will normally be satisfactory.
A wide variety of polymers are available for use in the present invention. The polymer should be capable of ready solidification to form a membrane having the desired transport properties, and insoluble in water or saline at cellular pH.
117~t30 The desired transport properties, e.g. permeability in vivo, require that the polymer have a degree of polarity. The polymer membrane should contain 20-90~ water at equilibrium. The polymer should be non-toxic in solution, and biocombatible in solid form, i.e. free from elutable contaminants, sterilizable, implantable without causing inflammatory or immune response, and either non-biodegradable or of controlled biodegradability.
Examples of suitable polymers include polyacrylates and copolymers with acrylic acid, methacrylic acid and esters thereof, cellulose based polymers, copolymers containing acrylamides, N-vinyl pyrrolidone, styrene sulphonate, vinyl pyridine, vinyl alcohol, allyl alcohol and the like. A
mostpreferred polymer is a copolymer of acrylic acid ester and methacrylic acid ester, with small amounts of quaternary ammonium groups. A specific example of such a preferred polymer, commercially available, is that known under the trade mark EUDRAGIT, manufactured by Rohm Pharma GMBH, of Darmstadt, W.Germany. This product is commonly used to coat dry tablets in slow release formulations.
The precise manner in which the polymer is precipitated onto the cells to form the membrane is not critical so long as a satisfactory encapsulation of a few cells to form encapsulated beads is achieved, without of course affecting the cells themselves. In a preferred method, the polymer solution in DMSO
is added to the well stirred aqueous cell emulsion in PPG, with :117~6~0 the result that the polymer precipitates at the interface of the water droplets to form a membrane shell about each droplet. In one alternative where, the cell emulsion is dispersed in the polymer solution, the polymer solution (containing dispersed cells) is added slowly to a polymer non-solvent to precipitate the polymer around the aqueous droplets. In another alternative, the polymer solution (containing dispersed cells) is added slowly to a polymer non-solvent immiscible with the polymer solvent, and then a second, miscible non-solvent is added slowly to this mixture to precipitate the polymer. Both the non-solvent and the solvent should of course be non-toxic, have low water solubility and high molecular weight. The non-solvent may be an isotonic aqueous solution at cellular pH, A with or without surfactants (e.g. Tweens, Pluronics etc.) or other additives such as albumin. The non-solvent may be an organic liquid miscible with the polymer solvent, non-toxic, and hydrophobic ana of high molecular weight (greater than 150) so that it does not penetrate the cells. Suitable examples are mineral oils, polyethers and polyether copolymers, natural and synthetic di-and tri-glycerides (e.g. corn oil, cotton seed oil etc.) and the like.
The choice of polymer solvent must be made with care.
Since, in order to provide a membrane with suitable transport properties when encapsulating the cells, a polar polymer must be used, the solvent liquid must also have a degree of polarity.
~ r~ `k~
At the same time, one must choose a polymer having low specific toxicity, often an incompatible requirement. The best solvents for use in the present invention are either relatively high molecular weight, medium polarity, non-toxic solvents with no or negligible water solubility, such as dimethyl phthalate, dibutyl phthalate, and the like, or highly polar water soluble solvents such as dimethyl-sulfoxide and the like. In the first alternative method of encapsulating the cells outlined above, in which the polymer solution is added to a suspension of aqueous cells in, e.g. polypropylene glycol, dimethyl sulfoxide (DMSO) is the most preferred solvent, since this process can utilise a water miscible solvent such as DMSO, which also has other advantageous characteristics. Suitable alternative solvents for this process are highly polar, water soluble, and tolerated by the cells at least to a limited extent. In the second and third processes where the aqueous cell suspension is dispersed in the polymer solution, then the polymer solvent must be water immiscible. In this case, the solvent should have intermediate polarity, very low toxicity, and be one which does not penetrate the cells. It should have a water solubility less than aboutO.5gm per 100 millilitres. Solvents containing moderately hydrogen bonding functional groups (ester, ether, carbonyl or S=O groups, for example) as set out in the "Polymer Handbook", srandrup and Immergut (Chapter 4), first edition, with a solubility parameter between 8 and 11, e.g. dialkyl phthalates ~17~ 3 and esters of dicarbo~ylic acids, are generally suitable. It is preferred to use solvents of molecular weight at least 150, otherwise the contact time of the solvent with the cells must be careully reduced. Most preferred solvents for use in this process are dibutyl phthalate, diethylphthalate and dimethylphthalate.
After the polymer has been precipitated to encapsulate the cells, it is necessary to separate the cells from the liquid residues. This can done by centrifuging after a suitable period of time, followed by decanting off the residual solvent/non-solvent mixture and washing to remove residues thereof. Great care should be taken to rinse DMSO from the cells. The cells should be washed repeatedly in aqueous solution of DMSO of progressively lower concentrations to minimize the osmotic gradient. Alternatively, the DMSO may be removed by dialysis during or after encapsulation. When dialysis is conducted during encapsulation, the bottom of the encapsulation chamber may be formed as a membrane permeable to DMSO but impermeable tothe hydrophobic non solvent, contacting a chamber containing saline. The encapsulation medium may be continuously dialysed against saline, in a separate unit, connected by a pump with the encapsulation unit.
It may be found advantageous to add various agents (e.g. albumin, clacium alginate and the like) to the initial cell emulsion to assist in preserving the cells during subsequent processing steps.
It may also be found advantageous to add a surfactant (e.g. PLURONIC L62*, from BASF Wyandotte) prior to centrifuging to assist in preventing the soft beads from coalescing during centrifugation. After separation, it is desirable to treat the encapsulated cell beads with an isotonic saline solution, with mixing, one or more times, to "harden" the membrane shell and prepare beads of appropriate quality and integrity. Then the viable cells are ready for preparation into appropriate dosage form, and administration to a body in an appropriate manner.
The invention is further illustrated in the following specific examples.
EXAMPLE l EUDRAGIT RL (Rohm Pharma Gmbh., Darmstadt, ~. Germany), -an acrylic acid ester/methacrylic acid ester copolymer containing a low content of quaternary ammonium groups was dissolved in a 75/25 (v/v) mixture of ethyl acetate and DMSO.
0.2 mL of this solution (27.4% w/v polymer was added, slowly, over a two minute period, to a well-stirred dispersion containing 0.4 mL of human whole blood or packed cells suspended in aqueous phosphate buffered saline (Red Cross Blood Bank, Toronto, Ontario) in 25 mL of mineral oil. Stirring was continued for a further 3 minutes.
5 mL of PBS (phosphate buffered saline) containing 15%
DMSO (v/v) was added to the dispersion and the mixture was centrifuged at low speed to remove the mineral oil supernatant.
*Trade Mark 46~)0 The DMSO was removed gradually in subsequent 5 mL washes followed by centrifugation with PBS containing progressively lower concentrations of DMSO (10%, 5%, 0~, DMSO).
Three further washes with pure PBS, followed by centrifugation at low speed, were used to separate free or partially encapsulated cells from the microcapsules.
Microscopic examination was used to assess qualitatively the effectiveness of the encapsulation process.
Cell lysis was quantified by spectrophotometric measurement of cyanmethemoglobin at 540 nm. Average capsule diameter was approximately 150 m. The cells, unchanged in colour, were encapsulated in clumps, but with the cell membrane distinctly separating individual cells. The cells were not uniformly distributed among the capsules, however.
With each wash the mixture was separated into three fractions:
micro-capsules containing cells, free cells and an aqueous supernatant containing some hemoglobin. The free cells which had been subject to the encapsulation conditions yet not encapsulated appeared intact microscopically (normal shape), took up oxygen freely, (turned bright pink when air was bubbled through an aliquot of resuspended cells) and lysed normally when placed in distilled water. In contrast, free cells after encapsulation using a pure DMSO solution of polymer were fixed, did not lyse in distilled water and had turned brown.
~1746~0 The estimated yield of encapsulated cells from whole blood was approximately 1-6% as determined by comparing the total amount of hemoglobin in the unencapsulated fractions (free cells and lysate) with the amount of hemoglobin in 12 drops of whole blood. Under the indicated experimental conditions, approximately 20% of the hemoglobin of the non-encapsulated cells was recovered as free hemoglobin during the aqueous washing steps. About 40-45% of this (i.e. 8-9% of the total) was recovered in the initial 15% DMSO/PBS wash; this represents the degree of cell lysis that occurred during both encapsulation and this initial wash step.
Encapsulated cells placed in distilled water lost hemoglobin slowly (overnight) to the surrounding fluid, indicating the low permeability of the EUDRAGIT capsules to proteins as large as hemoglobin. Spectrophotometric analysis of the distilled water supernatant indicated that the hemoglobin was not oxidized and that approximately 6% of the total cells were originally encapsulated, in agreement with the number estimated by hemoglobin balance for this batch of cells.
Hemoglobin did not leak from encapsulated cells placed in PBS, indicating that the encapsulated cells were intact, but were not fixed, lysing normally in hypotonic solutions. Removing the polymer coating by placing the capsules that had been in PBS in pure DMSO produced a brown pellet of fixed cells but no such pellet was found with the capsules that had been in distilled 11746Q(~
water, further indicating the intact state of the encapsulated cells.
Unlike conventional coacervation methods in which a non-solvent is added to a suspension of cells or other material in a polymer/solvent continuous medium to precipitate the polymer around the discrete phase, this method appears to rely on the high partition coefficient of DMSO between water and mineral oil. The DMSO solubilized the polymer in the mineral oil.
Because of the high partition coefficient, however, the DMSO was removed from the oil phase in the presence of the discrete aqueous phase. The removal of the solubilizing agent caused the polymer to precipitate at the water/oil interface. Accordingly the capsule was formed very rapidly ( 5 minutes), since the rate of capsule formation was limited by the rate of DMSO
removal and not by the slower rate of coacervate formation.
Other polar solvents (e.g. ethanol) were found to be appropriate for microcapsule formation but they were incompatible with the cells.
0.2 mL of washed packed red blood cells suspended in phosphate buffered saline was further dispersed in 5 mL of a 8 solution of EUDRAGIT RL in diethylphthalate. 4 mL of this mixture was dispersed in 20 mL of mineral oil to which 10 mL of corn oil was quickly added followed by stirring for 10 minutes.
After capsules had formed, a further 10 mL of corn oil was ~1746(~0 added, removed by decantation and followed by washing with 30 mL
of fresh corn oil and then 30 mL of mineral oil. The mineral oil phase was replaced with 10 mL PBS followed by centrifugation to yield hard, nonsticky, essentially spherical capsuls.
0.05 mL of washed packed red blood cells suspended in 0.05 mL of 9% bovine serum albumin aqueous solution was dispersed in 0.4 mLs of a 10% solution of Eudragit RL in dimethyl phthalate also containing 10% albumin. This mixture was added dropwise through an unstirred layer of corn oil (10 mL) into an unstirred bath of 2% albumin in PBS solution (100 mL). After all the cells were added the mixture was stirred for 15 minutes to further harden the capsules and remove the solvent. The capsules were recovered by centrifugation and washed twice with 2% albumin PBS to yield a hard granular product.
Encapsulated, viable mammalian cells according to the present invention have many useful applications of potential importance. For example, encapsulation of hepatocytes results in a functioning "artificial liver" for the treatment of acute hepatic coma or for drug detoxification. Encapsulation of interferon producing cells (e.g., human leukocytes, fibroblasts or lymphocytes) may facilitate the large scale production of interferon by increasing the surface-to-volume ratio of the culture, by increasing the stability of the cell and by simplifying the scale-up of the production process.
Claims (15)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A process for preparing micro-encapsuiated viable mammalian cells for introduction into host, living mammalian tissue, which comprises:
(a) preparing an aqueous suspension of said viable mammalian cells;
(b) bringing said aqueous suspension into contact with a solution of a biocompatible, water insoluble polymer in a polar, non-toxic liquid and forming a suspension having aqueous droplets containing said viable cells dispersed in a hydrophobic liquid medium;
(c) causing the polymer to precipitate at the interface of the aqueous, cell-containing droplets and the hydrophobic phase so as to encapsulate some at least of the cells in said droplets with a membrane of said polymer;
(d) separating the bulk of the hydrophobic medium from the encapsulated cellular material.
(a) preparing an aqueous suspension of said viable mammalian cells;
(b) bringing said aqueous suspension into contact with a solution of a biocompatible, water insoluble polymer in a polar, non-toxic liquid and forming a suspension having aqueous droplets containing said viable cells dispersed in a hydrophobic liquid medium;
(c) causing the polymer to precipitate at the interface of the aqueous, cell-containing droplets and the hydrophobic phase so as to encapsulate some at least of the cells in said droplets with a membrane of said polymer;
(d) separating the bulk of the hydrophobic medium from the encapsulated cellular material.
2. The process of claim 1 wherein the aqueous suspension of cells is dispersed in a relatively high molecular weight, hydrophobic, non-toxic, non-cell-penetrating liquid and agitated therein to form an emulsion having a discontinuous aqueous phase comprising droplets containing small numbers of said viable cells, and then the solution of water-insoluble polymer is added to said emulsion to precipitate the polymer.
3. The process of claim 1 including the further step of treating the encapsulated cellular material with saline to effect hardening of the polymeric membrane.
4. The process of claim 1, claim 2 or claim 3 wherein said separation of the hydrophobic medium from encapsulated cellular material is effected by centrifugation in the presence of surfactant, to retard coalescence of the beads of encapsulated cellular material.
5. The process of claim 2 wherein the hydrophobic liquid is polypropylene glycol or mineral oil.
6. The process of claim 5 wherein the polymer is a copolymer of acrylic acid ester and methacrylic acid ester with a low content of quaternary ammonium groups.
7. The process of claim 6 wherein the polymer is in solution in dimethyl sulphoxide.
8. The process of claim 1, claim 2 or claim 3 wherein polymer precipitation at the aqueous phase-hydrophobic phase interface is effected by slow addition to the mixture of a non-solvent for said polymer.
9. The process of claim 1 wherein the aqueous suspension of viable cells is added to a solution of polymer in a water immiscible solvent, followed by addition of non-solvent for the polymer to cause polymer precipitation.
10. The process of claim 9 wherein the polymer is a copolymer of acrylic acid ester and methacrylic acid ester with a low content of quaternary ammonium groups, the polymer solvent is diethylphthalate, dimethylphthalate or dibutylphthalate, and the polymer non-solvent is corn oil.
11. The process of claim 9 wherein the polymer membrane is treated with albumin after precipitation thereof.
12. Micro-encapsulated viable mammalian cells, said cells being in the form of discrete beads each containing a small number of said viable cells, and each bead being encapsulated in a semi-permeable, water-insoluble, biocompatible polymeric membrane capable of allowing passage therethrough of cell substrate material and cell secretions, but effectively preventing passage therethrough of high molecular weight antibodies of a living organism.
13. Micro-encapsulated viable mammalian cells according to claim 12 in which said polymeric membrane is formed of a copolymer of acrylic acid ester and methacrylic acid ester.
14. Micro-encapsulated viable mammalian cells according to claim 12 wherein the cells are viable pancreatic islet cells.
15. Micro-encapsulated viable mammalian cells according to claim 12 wherein the cells are human erythrocytes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/219,238 | 1980-12-23 | ||
| US06/219,238 US4353888A (en) | 1980-12-23 | 1980-12-23 | Encapsulation of live animal cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1174600A true CA1174600A (en) | 1984-09-18 |
Family
ID=22818459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000392774A Expired CA1174600A (en) | 1980-12-23 | 1981-12-21 | Encapsulation of live animal cells |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US4353888A (en) |
| CA (1) | CA1174600A (en) |
Families Citing this family (253)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4431428A (en) * | 1981-09-30 | 1984-02-14 | Trimedyne, Inc. | Bio-artificial organ using microencapsulated enzymes |
| US4758437A (en) * | 1981-12-23 | 1988-07-19 | Yamanouchi Pharmaceutical Co., Ltd. | Composition for long acting nicardipine preparation and process of producing the composition |
| SE441009B (en) * | 1982-03-08 | 1985-09-02 | Kjell Nilsson | WAY TO IMMOBILIZE LIVING BIOMATERIAL IN PEARLY POLYMERS |
| US4798786A (en) * | 1982-05-06 | 1989-01-17 | Stolle Research And Development Corporation | Living cells encapsulated in crosslinked protein |
| US4806355A (en) * | 1983-06-06 | 1989-02-21 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
| US4689293A (en) * | 1983-06-06 | 1987-08-25 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
| DE3376660D1 (en) * | 1983-06-22 | 1988-06-23 | Stolle Res & Dev | Encapsulated cells, their method of preparation and use |
| WO1985005630A1 (en) * | 1984-06-01 | 1985-12-19 | Karyon Technology, Incorporated | Tissue culture and production in permeable gels |
| US4778749A (en) * | 1984-06-01 | 1988-10-18 | Karyon Technology, Inc. | Tissue culture and production in permeable gels |
| NO166836C (en) * | 1985-03-14 | 1991-09-11 | Univ California | PROCEDURE FOR TREATMENT OF AN ORGAN TRANSPLANT. |
| US4690825A (en) * | 1985-10-04 | 1987-09-01 | Advanced Polymer Systems, Inc. | Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as a porogen |
| JPH0628570B2 (en) * | 1986-02-13 | 1994-04-20 | 雪印乳業株式会社 | Method and device for manufacturing capsule body |
| GB8604360D0 (en) * | 1986-02-21 | 1986-03-26 | Univ Dundee | Stimulation of hair growth |
| US4753635A (en) * | 1986-05-23 | 1988-06-28 | Jacqueline Sagen | Inducing analgesia by implantation of cells releasing neuroactive substances |
| US5026365A (en) * | 1987-04-29 | 1991-06-25 | The University Of Massachusetts | Method and apparatus for therapeutically treating immunological disorders and disease states |
| US4892538A (en) * | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5283187A (en) * | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5158881A (en) * | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US5871472A (en) * | 1987-11-17 | 1999-02-16 | Brown University Research Foundation | Planting devices for the focal release of neuroinhibitory compounds |
| US5418154A (en) * | 1987-11-17 | 1995-05-23 | Brown University Research Foundation | Method of preparing elongated seamless capsules containing biological material |
| US5605835A (en) * | 1988-05-23 | 1997-02-25 | Regents Of The University Of Minnesota | Bioreactor device with application as a bioartificial liver |
| US5023080A (en) * | 1988-06-17 | 1991-06-11 | Basic Bio Systems, Inc. | Time release protein |
| US5079005A (en) * | 1988-06-17 | 1992-01-07 | Gupta Kashmiri L | Time release protein |
| US5055300A (en) * | 1988-06-17 | 1991-10-08 | Basic Bio Systems, Inc. | Time release protein |
| US7238673B2 (en) * | 1989-03-31 | 2007-07-03 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| WO1990011734A1 (en) * | 1989-03-31 | 1990-10-18 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5698531A (en) | 1989-03-31 | 1997-12-16 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5101814A (en) * | 1989-08-11 | 1992-04-07 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
| US5190041A (en) * | 1989-08-11 | 1993-03-02 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
| US5427940A (en) * | 1991-06-03 | 1995-06-27 | Board Of Regents, The University Of Texas System | Engineered cells producing insulin in response to glucose |
| US5744327A (en) * | 1990-02-20 | 1998-04-28 | Board Of Regents, The University Of Texas System | Methods for producing insulin in response to non-glucose secretagogues |
| US5314471A (en) * | 1991-07-24 | 1994-05-24 | Baxter International Inc. | Tissue inplant systems and methods for sustaining viable high cell densities within a host |
| US5344454A (en) * | 1991-07-24 | 1994-09-06 | Baxter International Inc. | Closed porous chambers for implanting tissue in a host |
| DK0507933T3 (en) * | 1990-10-31 | 1996-06-17 | Baxter Int | Near-vascularizing implant material |
| US5800829A (en) * | 1991-04-25 | 1998-09-01 | Brown University Research Foundation | Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core |
| ES2107537T3 (en) * | 1991-04-25 | 1997-12-01 | Univ Brown Res Found | IMMUNO INSULATED BIOCOMPATIBLE VEHICLE IMPLANTABLE TO SUPPLY SELECTED THERAPEUTIC PRODUCTS. |
| US5792656A (en) * | 1991-06-03 | 1998-08-11 | Board Of Regents, The University Of Texas System | Methods of preparing genetically engineered cells that produce insulin in response to glucose |
| US5232712A (en) * | 1991-06-28 | 1993-08-03 | Brown University Research Foundation | Extrusion apparatus and systems |
| JPH06509329A (en) * | 1991-06-28 | 1994-10-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Treatment of diseases by site-specific infusion of cells or site-specific transformation of cells and kits therefor |
| US5453278A (en) * | 1991-07-24 | 1995-09-26 | Baxter International Inc. | Laminated barriers for tissue implants |
| US6773458B1 (en) * | 1991-07-24 | 2004-08-10 | Baxter International Inc. | Angiogenic tissue implant systems and methods |
| JP3252361B2 (en) * | 1991-10-02 | 2002-02-04 | ミルトン・エイチ・リプスキー | Assays for treating cancer in vivo |
| JPH07503943A (en) * | 1991-10-29 | 1995-04-27 | クローバー コンソリデイテッド，リミテッド | Cross-linked polysaccharides, polycations and lipids useful for encapsulation and drug release |
| JPH08500255A (en) * | 1992-04-01 | 1996-01-16 | バクスター・インターナショナル・インコーポレーテッド | Angiogenic tissue transplantation system and method thereof |
| US5955095A (en) * | 1992-04-22 | 1999-09-21 | Brown University Research Foundation | Microporous macrocapsules |
| US5286495A (en) * | 1992-05-11 | 1994-02-15 | University Of Florida | Process for microencapsulating cells |
| EP0655910A4 (en) * | 1992-07-29 | 1996-02-28 | Univ Washington | Use of pouch for implantation of living cells. |
| KR950703910A (en) | 1992-11-16 | 1995-11-17 | 윌리암 엠.잭슨 | Microporous Macrocapsules (MICROPOROUS MACROCAPSULES) |
| US5698413A (en) * | 1993-05-05 | 1997-12-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of evaluating chemotherapeutic agents in vivo |
| WO1995001203A2 (en) * | 1993-06-23 | 1995-01-12 | Cytotherapeutics, Inc. | Implantable membrane encapsulation apparatus |
| US5562909A (en) * | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
| AU678843B2 (en) | 1993-08-10 | 1997-06-12 | W.L. Gore & Associates, Inc. | Cell encapsulating device |
| ATE218893T1 (en) * | 1993-08-12 | 2002-06-15 | Neurotech Sa | BIOCOMPATIBLE IMMUNOISOLATION CAPSULES CONTAINING GENETICALLY MODIFIED CELLS |
| US5908623A (en) * | 1993-08-12 | 1999-06-01 | Cytotherapeutics, Inc. | Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
| US5453368A (en) * | 1993-08-27 | 1995-09-26 | Brown University Research Foundation | Method of encapsulating biological substances in microspheres |
| CA2148354A1 (en) * | 1993-09-24 | 1995-03-30 | Laura A. Martinson | Methods for enhancing vascularization of implant devices |
| US5550050A (en) * | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
| US5651980A (en) * | 1994-04-15 | 1997-07-29 | Biohybrid Technologies, Inc. | Methods of use of uncoated gel particles |
| US6156305A (en) * | 1994-07-08 | 2000-12-05 | Baxter International Inc. | Implanted tumor cells for the prevention and treatment of cancer |
| US20030152909A1 (en) * | 1994-11-16 | 2003-08-14 | Mitrani Eduardo N. | In vitro micro-organs, and uses related thereto |
| US6372482B1 (en) | 1997-01-16 | 2002-04-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Device and method for performing a biological modification of a fluid |
| US6126936A (en) * | 1995-03-10 | 2000-10-03 | Biohybrid Technologies Llc | Microcapsules and composite microreactors for immunoisolation of cells |
| US6132463A (en) | 1995-05-19 | 2000-10-17 | Etex Corporation | Cell seeding of ceramic compositions |
| US5741685A (en) * | 1995-06-07 | 1998-04-21 | Children's Medical Center Corporation | Parenchymal cells packaged in immunoprotective tissue for implantation |
| WO1997010807A1 (en) * | 1995-09-22 | 1997-03-27 | Gore Hybrid Technologies, Inc. | Improved cell encapsulation device |
| DE69634859D1 (en) * | 1995-10-26 | 2005-07-21 | Paul P Latta | INDUCTION OF IMMUNOLOGICAL TOLERANCE |
| CA2161863A1 (en) * | 1995-10-31 | 1997-05-01 | Michael Vivian Sefton | Angiogenic material and uses thereof |
| US5854067A (en) * | 1996-01-19 | 1998-12-29 | Board Of Regents, The University Of Texas System | Hexokinase inhibitors |
| US6087129A (en) | 1996-01-19 | 2000-07-11 | Betagene, Inc. | Recombinant expression of proteins from secretory cell lines |
| WO1997029701A1 (en) | 1996-02-15 | 1997-08-21 | Biosense Inc. | Catheter based surgery |
| US6027721A (en) * | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
| US6443974B1 (en) * | 1996-07-28 | 2002-09-03 | Biosense, Inc. | Electromagnetic cardiac biostimulation |
| US6200589B1 (en) | 1996-09-13 | 2001-03-13 | The University Of Akron | Biological implants of semipermeable amphiphilic membranes |
| US8728536B2 (en) * | 1996-10-16 | 2014-05-20 | Etex Corporation | Chemotherapeutic composition using nanocrystalline calcium phosphate paste |
| US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
| US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
| US6741877B1 (en) * | 1997-03-04 | 2004-05-25 | Dexcom, Inc. | Device and method for determining analyte levels |
| US6862465B2 (en) | 1997-03-04 | 2005-03-01 | Dexcom, Inc. | Device and method for determining analyte levels |
| US8527026B2 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
| US6558321B1 (en) | 1997-03-04 | 2003-05-06 | Dexcom, Inc. | Systems and methods for remote monitoring and modulation of medical devices |
| US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
| WO1998057663A1 (en) | 1997-06-17 | 1998-12-23 | University Technology Corporation | Neural transplantation for treating neurological disease |
| US6287558B1 (en) | 1997-08-01 | 2001-09-11 | Biohybrio Technologies Llc | Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule |
| AU8692598A (en) | 1997-08-04 | 1999-02-22 | Calydon, Inc. | A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof |
| US7687057B2 (en) | 1998-01-09 | 2010-03-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | In vitro micro-organs, and uses related thereto |
| US20030113303A1 (en) * | 1998-02-05 | 2003-06-19 | Yitzhack Schwartz | Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances |
| US20030129750A1 (en) * | 1998-02-05 | 2003-07-10 | Yitzhack Schwartz | Homing of donor cells to a target zone in tissue using active therapeutics or substances |
| DE69838526T2 (en) | 1998-02-05 | 2008-07-03 | Biosense Webster, Inc., Diamond Bar | Device for releasing a drug in the heart |
| US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
| US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6593133B1 (en) | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
| WO2000029206A1 (en) * | 1998-11-13 | 2000-05-25 | Sensor Technologies Inc. | Monodisperse preparations useful with implanted devices |
| US6291516B1 (en) * | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
| US6365385B1 (en) | 1999-03-22 | 2002-04-02 | Duke University | Methods of culturing and encapsulating pancreatic islet cells |
| US6303355B1 (en) | 1999-03-22 | 2001-10-16 | Duke University | Method of culturing, cryopreserving and encapsulating pancreatic islet cells |
| EP1374889A1 (en) * | 1999-06-25 | 2004-01-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of inducing angiogenesis by micro-organs |
| US8147824B2 (en) | 1999-08-05 | 2012-04-03 | Athersys, Inc. | Immunomodulatory properties of multipotent adult progenitor cells and uses thereof |
| US6793677B2 (en) * | 1999-08-13 | 2004-09-21 | Bret A. Ferree | Method of providing cells and other biologic materials for transplantation |
| WO2001013119A1 (en) | 1999-08-17 | 2001-02-22 | Luminex Corporation | Encapsulation of fluorescent particles |
| US6878543B1 (en) * | 1999-10-25 | 2005-04-12 | Nsgene Sa | Cultures of GFAP+ nestin+ cells that differentiate to neurons |
| CA2361563A1 (en) * | 1999-12-08 | 2001-06-14 | Ljubov Leonidovna Mironova | Use of polyacrylamide gel for forming a connective-tissue capsule in a mammal for cultivating allogenic or xenogenic cells |
| US7115653B2 (en) * | 2000-03-30 | 2006-10-03 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| US6683108B1 (en) | 2000-03-30 | 2004-01-27 | Curis, Inc. | Agonists of hedgehog signaling pathways and uses related thereto |
| US6613798B1 (en) | 2000-03-30 | 2003-09-02 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| US8852937B2 (en) * | 2000-03-30 | 2014-10-07 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| US20050070578A1 (en) * | 2000-03-30 | 2005-03-31 | Baxter Anthony David | Small organic molecule regulators of cell proliferation |
| EP1978090A1 (en) | 2000-08-09 | 2008-10-08 | ES Cell International Pte Ltd. | Pancreatic progenitor cells |
| US6908732B2 (en) | 2000-10-13 | 2005-06-21 | President & Fellows Of Harvard College | Compounds and methods for regulating cell differentiation |
| US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
| US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
| US7041468B2 (en) | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
| US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
| US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
| US8501396B2 (en) | 2001-11-05 | 2013-08-06 | Medgenics Medical Israel Ltd. | Dermal micro-organs, methods and apparatuses for producing and using the same |
| US8088568B2 (en) * | 2001-11-05 | 2012-01-03 | Medgentics, Inc. | Dermal micro-organs, methods and apparatuses for producing and using the same |
| US7468242B2 (en) | 2001-11-05 | 2008-12-23 | Medgenics, Inc. | Dermal micro organs, methods and apparatuses for producing and using the same |
| US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
| US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US8858434B2 (en) | 2004-07-13 | 2014-10-14 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US7379765B2 (en) | 2003-07-25 | 2008-05-27 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
| EP1496905B1 (en) | 2002-04-22 | 2008-08-13 | Johns Hopkins University School of Medicine | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| US20050008629A1 (en) * | 2002-05-08 | 2005-01-13 | Interpore Orthopaedics, A Delaware Corporation | Encapsulated AGF cells |
| EP1458853B1 (en) * | 2002-05-16 | 2009-11-25 | Absorber AB | Methods of donor specific crossmatching |
| US7226978B2 (en) | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
| JP2005533102A (en) * | 2002-07-12 | 2005-11-04 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム | Method and apparatus for inducing biological processes by micro-organs |
| JP4571776B2 (en) * | 2002-11-05 | 2010-10-27 | Ｊｘ日鉱日石エネルギー株式会社 | Lubricating oil composition |
| EP1581640A2 (en) * | 2002-12-24 | 2005-10-05 | An-Go-Gen Inc. | Encapsulated cells for therapy |
| US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
| CA2521623C (en) * | 2003-04-11 | 2015-03-17 | Etex Corporation | Osteoinductive bone material |
| EP1618179B1 (en) | 2003-04-18 | 2014-05-07 | Biogen Idec MA Inc. | Polymer-conjugated glycosylated neublastin |
| CA2788000C (en) | 2003-05-01 | 2016-03-15 | Medgenics Inc. | Apparatus for harvesting a dermal micro-organ |
| US7875293B2 (en) | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
| US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
| WO2007120442A2 (en) | 2003-07-25 | 2007-10-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US6931327B2 (en) | 2003-08-01 | 2005-08-16 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US20140121989A1 (en) | 2003-08-22 | 2014-05-01 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
| US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
| CA2536565A1 (en) * | 2003-09-10 | 2005-05-12 | Althea Technologies, Inc. | Expression profiling using microarrays |
| WO2005033297A1 (en) * | 2003-09-19 | 2005-04-14 | The Rockefeller University | Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells |
| US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
| US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| EP1711790B1 (en) | 2003-12-05 | 2010-09-08 | DexCom, Inc. | Calibration techniques for a continuous analyte sensor |
| CA2555894A1 (en) * | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| EP1737949B1 (en) * | 2004-03-09 | 2010-09-15 | Absorber AB | Endothelial progenitor cells and methods of use thereof |
| WO2005095450A2 (en) | 2004-03-30 | 2005-10-13 | Nsgene A/S | Therapeutic use of a growth factor, nsg33 |
| EP1742648A4 (en) * | 2004-04-15 | 2009-03-04 | Etex Corp | Delayed-setting calcium phosphate pastes |
| US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
| CA2571218C (en) | 2004-06-17 | 2015-11-03 | William D. Carlson | Tdf-related compounds and analogs thereof |
| US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
| US7905833B2 (en) | 2004-07-13 | 2011-03-15 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US20060270922A1 (en) | 2004-07-13 | 2006-11-30 | Brauker James H | Analyte sensor |
| US7857760B2 (en) | 2004-07-13 | 2010-12-28 | Dexcom, Inc. | Analyte sensor |
| WO2006013462A2 (en) * | 2004-07-30 | 2006-02-09 | Nsgene A/S | Growth factors nsg28, nsg30, and nsg32 |
| MX2007002029A (en) * | 2004-08-19 | 2007-03-28 | Biogen Idec Inc | Neublastin variants. |
| CN101043899B (en) * | 2004-08-19 | 2011-03-30 | 比奥根艾迪克Ma公司 | Refolding transforming growth factor beta family proteins |
| US7713542B2 (en) | 2005-01-14 | 2010-05-11 | Ada Foundation | Three dimensional cell protector/pore architecture formation for bone and tissue constructs |
| WO2006084284A2 (en) * | 2005-01-31 | 2006-08-10 | Cognate Therapeutics, Inc. | Adipose derived adult stromal cells exhibiting characteristics of endothelial cells |
| CN103356707B (en) | 2005-03-31 | 2016-07-06 | 斯丹姆涅恩有限公司 | Prepare in order to treat wound or the ulcer of diabetic neuropathy initiation, or the method for the medicine of prevention postoperative hernia formation |
| WO2006110193A2 (en) | 2005-04-08 | 2006-10-19 | Dexcom, Inc. | Cellulosic-based interference domain for an analyte sensor |
| US8744546B2 (en) | 2005-05-05 | 2014-06-03 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
| WO2006119439A2 (en) * | 2005-05-03 | 2006-11-09 | Althea Technologies, Inc. | Compositions and methods for the analysis of degraded nucleic acids |
| US20090169523A1 (en) | 2005-06-13 | 2009-07-02 | Catherine Verfaillie | Hsc self-renewal |
| TW200726474A (en) * | 2005-07-15 | 2007-07-16 | Cognate Therapeutics Inc | The immunophenotype and immunogenicity of human adipose derived cells |
| US8357666B2 (en) * | 2005-08-01 | 2013-01-22 | Nupotential, Inc. | Reprogramming a cell by inducing a pluripotent gene through RNA interference |
| US11000546B2 (en) | 2005-11-09 | 2021-05-11 | Athersys, Inc. | Immunomodulatory properties of MAPCs and uses thereof |
| US10117900B2 (en) * | 2005-11-09 | 2018-11-06 | Athersys, Inc. | MAPC treatment of brain injuries and diseases |
| US8147860B2 (en) | 2005-12-06 | 2012-04-03 | Etex Corporation | Porous calcium phosphate bone material |
| CN104027359A (en) | 2006-01-23 | 2014-09-10 | 阿特西斯公司 | MAPC Therapeutics Without Adjunctive Immunosuppressive Treatment |
| EP1981515B1 (en) | 2006-01-23 | 2013-04-24 | Athersys, Inc. | Mapc treatment of brain injuries and diseases |
| TWI501774B (en) * | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | Treatments for neurological disorders |
| ES2450065T3 (en) * | 2006-03-01 | 2014-03-21 | Biogen Idec Ma Inc. | Compositions and methods for the administration of GDNF ligand family proteins |
| EP1991110B1 (en) | 2006-03-09 | 2018-11-07 | DexCom, Inc. | Systems and methods for processing analyte sensor data |
| AU2007243946B2 (en) | 2006-04-05 | 2012-11-29 | Curis, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
| EP2029781A4 (en) * | 2006-05-26 | 2010-06-30 | Althea Technologies Inc | Biochemical analysis of partitioned cells |
| US7920907B2 (en) | 2006-06-07 | 2011-04-05 | Abbott Diabetes Care Inc. | Analyte monitoring system and method |
| AU2007275764B2 (en) | 2006-07-18 | 2013-11-14 | University Of Utah Research Foundation | Methods for treating pain and screening analgesic compounds |
| US8454948B2 (en) | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
| EP2061515A4 (en) * | 2006-09-14 | 2013-01-30 | Medgenics Medical Israel Ltd | Long lasting drug formulations |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| US20090214474A1 (en) * | 2006-11-01 | 2009-08-27 | Barbara Brooke Jennings | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| CN101680014B (en) | 2007-04-03 | 2018-09-28 | 奥克西雷恩英国有限公司 | The glycosylation of molecule |
| TWI445544B (en) * | 2007-05-01 | 2014-07-21 | Biogen Idec Inc | Compositions and methods for increasing vascularization |
| US8329467B2 (en) * | 2007-05-03 | 2012-12-11 | Fox Chase Cancer Center | Compositions and methods for altering pancreas or liver function |
| WO2008137281A1 (en) * | 2007-05-03 | 2008-11-13 | Fox Chase Cancer Center | Compositions and methods for altering pancreas or liver function |
| US20110135648A1 (en) * | 2007-08-08 | 2011-06-09 | Biogen Idec Ma Inc. | Anti-neublastin antibodies and uses thereof |
| WO2009092092A1 (en) | 2008-01-18 | 2009-07-23 | Regents Of The University Of Minnesota | Stem cell aggregates and methods for making and using |
| EP2274424A4 (en) | 2008-04-07 | 2012-02-01 | Nupotential Inc | Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator |
| WO2009155301A2 (en) * | 2008-06-17 | 2009-12-23 | The Mclean Hospital Corporation | Multipotent neural cells |
| US9198872B2 (en) | 2008-12-08 | 2015-12-01 | University Of Miami | Dendritic and hyperbranched polymers for cellular encapsulation and functionalization |
| US8728520B2 (en) * | 2008-12-08 | 2014-05-20 | University Of Miami | Cross-linked alginate-polyalkylene glycol polymer coatings for encapsulation and methods of making the same |
| EP3187581A1 (en) | 2008-12-23 | 2017-07-05 | BOCO Silicon Valley, Inc. | Target populations of oligodendrocyte precursor cells and methods of making and using same |
| WO2010111278A1 (en) | 2009-03-23 | 2010-09-30 | The Texas A&M University System | Compositions of mesenchymal stem cells to regenerate bone |
| BRPI0902039B8 (en) | 2009-06-09 | 2021-05-25 | Anhanguera Educacional Ltda | pharmaceutical composition and use of pharmaceutical composition for the treatment, prophylaxis or prevention of neoplastic diseases in humans and animals |
| WO2011039634A2 (en) | 2009-09-29 | 2011-04-07 | Universiteit Gent | Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose |
| GB0918564D0 (en) | 2009-10-22 | 2009-12-09 | Plasticell Ltd | Nested cell encapsulation |
| CN102834509A (en) | 2009-11-19 | 2012-12-19 | 奥克西雷恩英国有限公司 | Yeast strains producing mammalian-like complex N-glycans |
| JP2013520509A (en) | 2010-02-25 | 2013-06-06 | エイビーティー ホールディング カンパニー | Regulation of angiogenesis |
| SG183497A1 (en) | 2010-02-25 | 2012-09-27 | Abt Holding Co | Modulation of macrophage activation |
| US8993532B2 (en) | 2010-04-23 | 2015-03-31 | Cold Spring Harbor Laboratory | Structurally designed shRNAs |
| WO2011139688A2 (en) | 2010-04-28 | 2011-11-10 | The J. David Gladstone Institutes | Methods for generating cardiomyocytes |
| WO2011143415A1 (en) | 2010-05-12 | 2011-11-17 | Abt Holding Company | Modulation of splenocytes in cell therapy |
| ES2685171T3 (en) | 2010-06-14 | 2018-10-05 | The Scripps Research Institute | Reprogramming cells to a new destination |
| WO2011159758A2 (en) | 2010-06-15 | 2011-12-22 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
| WO2012027494A1 (en) | 2010-08-24 | 2012-03-01 | Regents Of The University Of Minnesota | Bispecific targeting reagents |
| SG189110A1 (en) | 2010-09-29 | 2013-05-31 | Oxyrane Uk Ltd | De-mannosylation of phosphorylated n-glycans |
| SG189108A1 (en) | 2010-09-29 | 2013-05-31 | Oxyrane Uk Ltd | Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins |
| AU2011307488B2 (en) | 2010-10-01 | 2015-08-20 | Hoba Therapeutics Aps | Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain |
| WO2012106281A2 (en) | 2011-01-31 | 2012-08-09 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
| DK2710124T3 (en) | 2011-05-20 | 2016-05-09 | Mclean Hospital Corp | NEURONAL PROGENITOR CELLS AND APPLICATIONS THEREOF |
| AU2012268441B2 (en) | 2011-06-06 | 2016-05-12 | Kineta One, Llc | ShK-based pharmaceutical compositions and methods of manufacturing and using the same |
| EP4344633A2 (en) | 2011-12-11 | 2024-04-03 | Abbott Diabetes Care, Inc. | Analyte sensor methods |
| KR20190114003A (en) | 2012-03-15 | 2019-10-08 | 옥시레인 유케이 리미티드 | Methods and materials for treatment of pompe's disease |
| CN104684561A (en) | 2012-08-01 | 2015-06-03 | 联合治疗公司 | Treatment of pulmonary arterial hypertension with mesenchymal stem cells |
| ES2713988T3 (en) | 2012-08-01 | 2019-05-24 | United Therapeutics Corp | Treatment of pulmonary arterial hypertension with endothelial progenitor cells treated with prostacyclin |
| US9605074B2 (en) | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
| EP3878452B1 (en) | 2013-01-09 | 2023-09-20 | United Therapeutics Corporation | Treatment of vasculopathy with prostacyclin and mesenchymal stem cells |
| EP2964758B1 (en) | 2013-03-05 | 2020-05-27 | Oxyrane UK Limited | Production of catalytically active type i sulfatase |
| CA2909267C (en) | 2013-04-12 | 2022-10-25 | Saverio LA FRANCESCA | Improving organs for transplantation |
| WO2014184666A2 (en) | 2013-04-30 | 2014-11-20 | Katholieke Universiteit Leuven | Cell therapy for myelodysplastic syndromes |
| TWI686205B (en) | 2013-05-31 | 2020-03-01 | 美國猶他大學研究基金會 | Conotoxin peptides, pharmaceutical compositions and uses thereof |
| WO2015042580A1 (en) | 2013-09-23 | 2015-03-26 | Biogen Idec Ma Inc. | Compositions and methods for treatment of neuropathic pain |
| WO2015069736A1 (en) | 2013-11-08 | 2015-05-14 | The Mclean Hospital Corporation | METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS |
| WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
| WO2016085765A1 (en) | 2014-11-25 | 2016-06-02 | President And Fellows Of Harvard College | Methods for generation of podocytes from pluripotent stem cells and cells produced by the same |
| WO2016183493A1 (en) | 2015-05-14 | 2016-11-17 | Abbott Diabetes Care Inc. | Compact medical device inserters and related systems and methods |
| US10213139B2 (en) | 2015-05-14 | 2019-02-26 | Abbott Diabetes Care Inc. | Systems, devices, and methods for assembling an applicator and sensor control device |
| US10697972B2 (en) | 2016-01-12 | 2020-06-30 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
| AU2017207263B2 (en) | 2016-01-12 | 2021-01-07 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
| WO2017202814A1 (en) | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons |
| KR102606101B1 (en) | 2016-10-24 | 2023-11-27 | 유나이티드 쎄러퓨틱스 코포레이션 | Enhancement of MSC immunomodulatory properties by treprostinil |
| CN110461217B (en) | 2017-01-23 | 2022-09-16 | 雅培糖尿病护理公司 | Systems, devices, and methods for analyte sensor insertion |
| GB201707143D0 (en) | 2017-05-04 | 2017-06-21 | Plasticell Ltd | Method for producing cells |
| EP3656851A1 (en) | 2018-11-23 | 2020-05-27 | Technische Universität Dresden | Artificial hla-positive feeder cell lines for nk cells and uses thereof |
| US20230383261A1 (en) | 2020-10-14 | 2023-11-30 | Sana Biotechnology, Inc. | Hepatocyte-like cells |
| IT202100006569A1 (en) | 2021-03-18 | 2022-09-18 | Hemera S R L | METHOD FOR OBTAINING REGENERATIVE MACROPHAGES EDUCATED FROM TUMOR AND THEIR USE IN REGENERATIVE MEDICINE |
| AU2022269279A1 (en) | 2021-05-06 | 2023-11-30 | Hoba Therapeutics Aps | Prevention and treatment of chemotherapy-induced neuropathic pain |
| WO2023081420A1 (en) | 2021-11-05 | 2023-05-11 | Abt Holding Company | Culture-expanded canine progenitor cells and related methods |
| WO2023104960A1 (en) | 2021-12-10 | 2023-06-15 | Hoba Therapeutics Aps | Treatment of nociceptive pain |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2053565A5 (en) * | 1969-07-09 | 1971-04-16 | Pasteur Institut | |
| US4036693A (en) * | 1976-02-02 | 1977-07-19 | Massachusetts Institute Of Technology | Treatment of cell culture microcarries |
| US4184922A (en) * | 1977-11-11 | 1980-01-22 | The Government Of The United States | Dual circuit, woven artificial capillary bundle for cell culture |
-
1980
- 1980-12-23 US US06/219,238 patent/US4353888A/en not_active Expired - Lifetime
-
1981
- 1981-12-21 CA CA000392774A patent/CA1174600A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| US4353888A (en) | 1982-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1174600A (en) | Encapsulation of live animal cells | |
| US5470731A (en) | Coated transplant and method for making same | |
| US4806355A (en) | Microencapsulation of living tissue and cells | |
| US4798786A (en) | Living cells encapsulated in crosslinked protein | |
| US8241652B2 (en) | Porous gelatin material, gelatin structures, methods for preparation of the same and uses thereof | |
| FI118853B (en) | Macroencapsulated secretory cells | |
| US5453368A (en) | Method of encapsulating biological substances in microspheres | |
| JPS6244919B2 (en) | ||
| CA1204058A (en) | Dual microcapsules | |
| JPS58500063A (en) | Pellet, microbead, microcapsule and their manufacturing method | |
| WO2000056861A1 (en) | Methods of microencapsulating pancreatic islet cells | |
| Sucamori et al. | Microencapsulation of pancreatic islets in a water insoluble polyacrylate | |
| Morelli et al. | Microparticles for cell encapsulation and colonic delivery produced by membrane emulsification | |
| GB2094750A (en) | Encapsulation and release of core material | |
| JP2022022330A (en) | Conformal coating on biological surfaces | |
| Sefton et al. | Microencapsulation of erythrocytes | |
| Lamberti et al. | Microencapsulation of erythrocytes in Eudragit-RL-coated calcium alginate | |
| EP0129619B1 (en) | Encapsulated cells, their method of preparation and use | |
| US6303355B1 (en) | Method of culturing, cryopreserving and encapsulating pancreatic islet cells | |
| Sefton et al. | Hydrophilic polyacrylates for the microencapsulation of fibroblasts or pancreatic islets | |
| Moustafa et al. | Viability and functionality of bovine chromaffin cells encapsulated into alginate-PLL microcapsules with a liquefied inner core | |
| JP2003504171A (en) | Preparation of multi-wall polymer microcapsules from hydrophilic polymers | |
| SU1666535A1 (en) | Method for preparation of immobilized cell of animal origin | |
| JPH05176754A (en) | Method for propagation of cell | |
| Rosinski et al. | Mass transfer ranking of polylysine, poly-ornithine and poly-methylene-co-guanidine microcapsule membranes using a single low molecular mass marker |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEC | Expiry (correction) | ||
| MKEX | Expiry |